RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor
about
Osteoprotegerin rich tumor microenvironment: implications in breast cancerPrinciples of antibody-mediated TNF receptor activationDimerization of LT R by LT 1 2 is necessary and sufficient for signal transductionSeroepidemiology of astrovirus MLB1Adenosine and bone metabolism.Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily membersExpression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin are associated with middle ear cholesteatoma risk.Correlating RANK ligand/RANK binding kinetics with osteoclast formation and functionVariants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.Testosterone regulates bone response to inflammation.A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis.RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare diseaseRegulation of bone and cartilage by adenosine signaling.The dual face of parathyroid hormone and prostaglandins in the osteoimmune system.Osteoprotegerin and kidney disease.Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis.Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures.Inflammatory osteolysis: a conspiracy against bone.Cellular and molecular pathways of structural damage in rheumatoid arthritis.Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats.Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction.Heterologous expression, purification and function of the extracellular domain of human RANK.Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis.Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women: a 12-week randomized double-blinded placebo-controlled trial.Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy.Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass.Sortase A-aided Escherichia coli expression system for functional osteoprotegerin cysteine-rich domain.Novel Insights on the Regulation of B Cell Functionality by Members of the Tumor Necrosis Factor Superfamily in Jawed Fish.Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.Peptides as Therapeutic Agents for Inflammatory-Related Diseases
P2860
Q26748804-2204ADE4-50CB-4285-92E2-5DE052055A3BQ26796270-381BDD99-2070-4813-ABD6-394555CFAA4FQ27680632-3C1E5020-2EFA-426D-87D5-3BA2DBEA6AD2Q33743398-FDE1011F-9CDE-450E-95AC-066D439D33F5Q34036039-1461A97E-BF39-4AD3-AD32-E3B1B65A276BQ34334341-64B1B3C9-12ED-4E42-A3E7-7BAF642E834AQ34386821-5D57773C-09A3-405F-8127-4398019BCA4FQ35587872-BF067BF4-CD47-46C4-ACBC-0D87F9E380BBQ35599724-BD4E8A07-209B-401E-8181-03DC4E9C0E70Q35611366-384ECEA4-7CCF-4FF7-8255-11E3166AF828Q35910549-DC73436B-074D-4322-A381-98B9B40CB71DQ36053859-2EFEB98E-CEB6-493F-90F1-D75B61829710Q36898545-A3C6C7DD-6892-4D01-9F01-A03D25DADAF4Q37442054-5FF48D81-7195-478F-BC4D-44F8957B1B89Q38138832-226BEBB4-1D98-44AA-9A11-A5C93059A967Q38206487-4D7FD240-0DED-4544-A1D3-A05B28EF65C1Q38742682-104111CB-5FE8-4DC1-BA52-03C6A918FCA1Q38771001-660346DB-4ED0-44E6-AE6F-0B0A2CAE684DQ39054114-AA9EC1B2-7A8B-498B-88EC-46C1E3EEF48CQ39059671-2F8D0B2A-DB33-4634-AA32-103134453A12Q39343563-5CF044A8-EE9D-4451-AF08-F758F09AF4ABQ39361224-01B02EBB-5F27-411C-A90C-8950FC83FD92Q40376112-A1620C53-A002-4227-875A-BDC1105B2A5AQ41513671-5BDF28AB-6EC3-4B94-A0E3-00DA52632BEFQ47141671-A2A0A937-A013-4196-847F-9E20AC89657DQ47292379-D085F76A-601D-484B-A0A4-93D3E3E35B6BQ47796713-118E6D06-A1B6-42FE-A374-5C14C76487F9Q50058106-900989A5-C814-4A0C-89CE-09F5EBF69FDAQ50071959-7BBF98EA-9CE0-4554-904A-D1470B1D29F9Q50130540-A965B98F-6470-4558-95B3-09A17B0B9018Q50673485-0F93B617-D61A-40D4-A161-E6DA3189E84BQ55277521-E9DAA7F2-888E-49FA-820B-E6B81C0E9E3EQ55406267-B0E99EEE-9A50-4D1A-9870-135A41BB4923Q58749714-B0F0AAEC-0141-4E58-B3FE-0F32661B6DDD
P2860
RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@ast
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@en
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@nl
type
label
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@ast
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@en
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@nl
prefLabel
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@ast
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@en
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@nl
P2093
P2860
P921
P3181
P1433
P1476
RANKL Employs Distinct Binding ...... Osteoprotegerin Decoy Receptor
@en
P2093
Christopher A Nelson
Daved H Fremont
Julia T Warren
Michael W-H Wang
P2860
P304
P3181
P356
10.1016/J.STR.2012.08.030
P577
2012-11-07T00:00:00Z